CyDex licenses Captisol for injectable zileuton
Kansas, USA-based CyDex has signed a license and supply agreement granting exclusive worldwide rights to its Captisol enabling technology to fellow USA-based Critical Therapeutics for the development of an injectable formulation of zileuton. Critical Therapeutics, and its co-promotion partner Dey, currently market the asthma drug as Zyflo in the USA.
On May 30, the US Food and Drug Administration approved twice-daily Zyflo CR extended-release tablets. Critical Therapeutics and Dey expect to begin marketing the drug in the USA in the fall. The agent is indicated for the prevention and treatment of asthma in adults and children 12 years of age and older.
The injectable formulation of zileuton is being developed for use in emergency room or urgent care settings for patients experiencing acute exacerbations of asthma. CyDex' patented Captisol technology improves water solubility, bioavailability and complexation characteristics of insoluble and/or unstable drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze